1
|
Yuste C, Passerat V, Calais G, Schipman B, Vaugier L, Paumier A, Huertas A, Hemery CG, Debelleix C, Chamois J, Blanchard N, Septans AL, Pointreau Y. Stereotactic body radiation therapy for adrenal gland metastases: A multi-institutional outcome analysis. Clin Transl Radiat Oncol 2024; 45:100708. [PMID: 38162282 PMCID: PMC10757246 DOI: 10.1016/j.ctro.2023.100708] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/27/2023] [Revised: 11/12/2023] [Accepted: 11/30/2023] [Indexed: 01/03/2024] Open
Abstract
Aim The adrenal gland is a common site of metastasis with a rate of up to 27% in autopsy series. The incidence of these metastases is increasing due to greater use of Positron Emission Tomography scans and improved overall survival of patients with metastatic cancers. Stereotactic body radiation therapy (SBRT) is a non-invasive treatment option for metastasis. The aim of this study is to assess prognostic factors influencing local control, progression-free and overall survival in oligometastatic patients treated with SBRT for an adrenal metastasis. Methods In this multicentric retrospective study, we included patients with adrenal metastases treated with SBRT between 2010 and 2021 in eleven french centers. All primary tumors were included. Results A total of 110 patients treated for 121 adrenal lesions were included. Non-small-cell lung cancer was the predominant histologic type (55.4 %). Eighty-two percent of patients had at least 2 metastatic sites. The median Planning Target Volume was 70 cm3 with a median prescription dose of 40 Gray (Gy). The mean Biologically Effective Dose (BED) 10 dose was 74.2 Gy. Local control at 1 and 2 years was 85.9 % and 72.5 % respectively. The median overall survival and progression-free survival were 31.6 and 8.5 months respectively. Local control was significantly improved by systemic treatment one month before or after SBRT (p = 0.009) and by a BED10 greater than or equal to 50 Gy (p = 0.003).In multivariate analysis, oligometastatic presentation (p = 0.009) and a metachronous metastatic presentation (p = 0.008) were independent factors for progression-free survival.Tolerance was excellent, no grade 3 and 4 toxicities were described due to SBRT. Conclusion Stereotactic radiotherapy of adrenal metastases makes possible a local control of more than 85% at one year and was well tolerated. The factors influencing survival in oligometastatic patients still need to be found in order to better select those who benefit the most from this type of treatment.
Collapse
Affiliation(s)
- C. Yuste
- Institut de Cancérologie de l'Ouest, Angers, France
| | - V. Passerat
- Centre Bayard, Orlam, Villeurbanne, France
- Colib – Club des Oncologues Libéraux, Le Mans, France
| | - G. Calais
- Colib – Club des Oncologues Libéraux, Le Mans, France
- Hôpital Bretonneau 2, clinique d'oncologie et de radiothérapie (CORAD), Tours, France
| | - B. Schipman
- Institut de Cancérologie de Bourgogne, Dijon, France
| | - L. Vaugier
- Institut de Cancérologie de l’Ouest, St Herblain, France
| | - A. Paumier
- Institut de Cancérologie de l'Ouest, Angers, France
| | - A. Huertas
- Institut de Radiothérapie Sud de l'Oise, Creil, France
| | - CG. Hemery
- Polyclinique de Courlancy, Reims, France
| | - C. Debelleix
- Clinique Bordeaux Tivoli-Ducos, Bordeaux, France
| | - J. Chamois
- Private Hospital, Saint-Grégoire, France
| | | | | | - Y. Pointreau
- Colib – Club des Oncologues Libéraux, Le Mans, France
- Hôpital Bretonneau 2, clinique d'oncologie et de radiothérapie (CORAD), Tours, France
- Weprom, Angers, France
- Institut inter-régional de Cancérologie (ILC) - Centre Jean Bernard, Le Mans, France
- Centre de Cancérologie de la Sarthe (CCS), Le Mans, France
| |
Collapse
|
2
|
Camps-Malea A, Pointreau Y, Chapet S, Calais G, Barillot I. Stereotactic body radiotherapy for mediastinal lymph node with CyberKnife®: Efficacy and toxicity. Cancer Radiother 2023; 27:225-232. [PMID: 37080855 DOI: 10.1016/j.canrad.2022.11.002] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/10/2022] [Revised: 11/21/2022] [Accepted: 11/22/2022] [Indexed: 04/22/2023]
Abstract
PUPRPOSE Stereotactic body radiotherapy is more and more used for treatment of oligometastatic mediastinal lymph nodes. The objective of this single-centre study was to evaluate its efficacy in patients with either a locoregional recurrence of a pulmonary or oesophageal cancer or with distant metastases of extrathoracic tumours. PATIENTS AND METHODS Patients with oligometastatic mediastinal lymph nodes treated with CyberKnife from June 2010 to September 2020 were screened. The primary endpoint was to assess local progression free survival and induced toxicity. Secondary endpoints were overall survival and progression free survival. The delay before introduction of systemic treatment in the subgroup of patients who did not receive systemic therapy for previous progression was also evaluated. RESULTS Fifty patients were included: 15 with a locoregional progression of a thoracic primary tumour (87% pulmonary) and 35 with mediastinal metastasis of especially renal tumour (29%). Median follow-up was 27 months (6-110 months). Local progression free survival at 6, 12 and 18 months was respectively 94, 88 and 72%. The rate of local progression was significantly lower in patients who received 36Gy in six fractions (66% of the cohort) versus other treatment schemes. Two grade 1 acute oesophagitis and one late grade 2 pulmonary fibrosis were described. Overall survival at 12, 18 and 24 months was respectively 94, 85 and 82%. Median progression free survival was 13 months. Twenty-one patients were treated by stereotactic body irradiation alone without previous history of systemic treatment. Among this subgroup, 11 patients (52%) received a systemic treatment following stereotactic body radiotherapy with a median introduction time of 17 months (5-52 months) and 24% did not progress. CONCLUSION Stereotactic body irradiation as treatment of oligometastatic mediastinal lymph nodes is a well-tolerated targeted irradiation that leads to a high control rate and delay the introduction of systemic therapy in selected patients.
Collapse
Affiliation(s)
- A Camps-Malea
- Service de radiothérapie, centre Henry-S-Kaplan, CHRU Bretonneau, Tours, France.
| | - Y Pointreau
- Service de radiothérapie, centre Henry-S-Kaplan, CHRU Bretonneau, Tours, France; Institut Inter-régional de cancérologie, centre Jean-Bernard, clinique Victor-Hugo, Le Mans, France
| | - S Chapet
- Service de radiothérapie, centre Henry-S-Kaplan, CHRU Bretonneau, Tours, France
| | - G Calais
- Service de radiothérapie, centre Henry-S-Kaplan, CHRU Bretonneau, Tours, France
| | - I Barillot
- Service de radiothérapie, centre Henry-S-Kaplan, CHRU Bretonneau, Tours, France
| |
Collapse
|
3
|
Legouté F, Lesueur P, El Kabbaj O, Ghannam Y, Michalet M, Monpetit E, Azria D, Giraud P, Calais G, Pointreau Y, Ollivier L. [French careers in oncology radiotherapy: Crossing views]. Cancer Radiother 2023; 27:75-79. [PMID: 36008260 DOI: 10.1016/j.canrad.2022.07.016] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/07/2022] [Revised: 07/03/2022] [Accepted: 07/04/2022] [Indexed: 02/06/2023]
Abstract
The French Society of Young Radiation Oncologists (SFjRO), the National Union of Radiation Oncologists (SNRO) and the French Society of Oncological Radiotherapy (SFRO) aim to reconcile career opportunities and demographic needs in oncology. In 2021, 932 radiation oncologists (RO) are in regular activity in France, this represents an increase of more than 20% in ten years. Physician distribution is changing in public hospitals, cancer centers and private clinics. Currently one third of ROs works in each sector. In addition, fifteen percent of ROs have a mixed activity. In 2021, 180 young RO (trainees and residents) were questioned by SFjRO board about their training, internship, coaching and career guidance. An interactive communication was organized during the 32nd SFRO Meeting in 2021. It was an opportunity to bring the results of this study. More than 70% RO interviewed answered to the survey, for 55% among them, career choice was difficult. In order to help young ROs in their professional approach, three RO made an oral presentation during this session, about radiotherapy in public hospitals, private centers or with a mixed practice. The aim of this article is to summarize the highlights of the last SFjRO/SFRO session: expectations of young RO, career prospects and trends.
Collapse
Affiliation(s)
- F Legouté
- Service de radiothérapie, centre hospitalier départemental Vendée, boulevard Stéphane-Moreau, 85000 La Roche-sur-Yon, France.
| | - P Lesueur
- Département de radiothérapie, centre François-Baclesse, Caen, France; Département de radiothérapie, centre Guillaume-le-Conquérant, Le-Havre, France
| | - O El Kabbaj
- Centre Saint-Yves-radiothérapie, 11, rue du Docteur-Audic, 56000 Vannes, France
| | - Y Ghannam
- Société française des jeunes radiothérapeutes oncologues (SFjRO), centre Antoine-Béclère, 47, rue de la Colonie, 75013 Paris, France; Département de radiothérapie, Institut de cancérologie de l'ouest, 15, rue André-Boquel, 49100 Angers, France
| | - M Michalet
- Société française des jeunes radiothérapeutes oncologues (SFjRO), centre Antoine-Béclère, 47, rue de la Colonie, 75013 Paris, France; Service d'oncologie radiothérapie, Institut du cancer de Montpellier, Montpellier, France
| | - E Monpetit
- Centre Saint-Yves-radiothérapie, 11, rue du Docteur-Audic, 56000 Vannes, France; Syndicat national des radiothérapeutes oncologues (SNRO), centre Saint-Yves radiothérapie, 11, rue du Docteur-Audic, 56000 Vannes, France
| | - D Azria
- Service d'oncologie radiothérapie, Institut du cancer de Montpellier, Montpellier, France; Société française de radiothérapie oncologique (SFRO), centre Antoine-Béclère, 47, rue de la Colonie, 75013 Paris, France
| | - P Giraud
- Société française de radiothérapie oncologique (SFRO), centre Antoine-Béclère, 47, rue de la Colonie, 75013 Paris, France; Service d'oncologie radiothérapie, hôpital européen Georges-Pompidou, université Paris Cité, AP-HP, 20, rue Leblanc, 75015 Paris, France
| | - G Calais
- Service de radiothérapie, centre régional universitaire de cancérologie Henry-S.-Kaplan, hôpital Bretonneau, CHRU de Tours, 2, boulevard Tonnellé, 37044 Tours, France
| | - Y Pointreau
- Service de radiothérapie, centre régional universitaire de cancérologie Henry-S.-Kaplan, hôpital Bretonneau, CHRU de Tours, 2, boulevard Tonnellé, 37044 Tours, France; Centre Jean-Bernard, clinique Victor-Hugo, (Institut interrégional de cancérologie), 9, rue Beauverger, 72000 Le Mans, France
| | - L Ollivier
- Société française des jeunes radiothérapeutes oncologues (SFjRO), centre Antoine-Béclère, 47, rue de la Colonie, 75013 Paris, France; Département de radiothérapie, Institut de cancérologie de l'ouest, boulevard Professeur-Jacques-Monod, 44800 Saint-Herblain, France
| |
Collapse
|
4
|
Dahan LS, Giorgi R, Vergez S, Le Taillandier de Gabory L, Costes-Martineau V, Herman P, Poissonnet G, Mauvais O, Malard O, Garrel R, Uro-Coste E, Barry B, Bach C, Chevalier D, Mouawad F, Merol JC, Bastit V, Thariat J, Gilain L, Dufour X, Righini CA, Moya-Plana A, Even C, Radulesco T, Michel J, Baujat B, Fakhry N, Albert S, Andry G, Babin E, Bach C, Badet JM, Badoual C, Baglin A, Banal A, Barry B, Baudin E, Baujat B, Bensadoun R, Bertolus C, Bessède JP, Blanchard D, Borel C, Bozorg-Grayeli A, Breheret R, Breton P, Brugel L, Calais G, Casiraghi O, Cassagnau E, Castillo L, Ceruse P, Chabolle F, Chevalier D, Chobaut J, Choussy O, Cosmidis A, Coste A, Costes V, Crampette L, Darrouzet V, Demez P, Dessi P, Devauchelle B, Dolivet G, Dubrulle F, Duflo S, Dufour X, Faivre S, Fakhry N, Ferron C, Floret F, de Gabory L, Garrel R, Geoffrois L, Gilain L, Giovanni A, Girod A, Guerrier B, Hans S, Herman P, Hofman P, Housset M, Jankowski R, Jegoux F, Juliéron M, Kaminsky MC, Kolb F, St Guily JL, Laccoureye L, Lallemant B, Lang P, Lartigau E, Lavieille JP, Lefevre M, Leroy X, Malard O, Massip F, Mauvais O, Merol JC, Michel J, Mom T, Morinière S, de Monès E, Moulin G, Noel G, Poissonnet G, Prades JM, Radulesco T, de Raucourt D, Reyt E, Righini C, Robin YM, Rolland F, Ruhin B, Sarroul N, Schultz P, Serrano E, Sterkers O, Strunski V, Sudaka A, Tassart M, Testelin S, Thariat J, Timochenko A, Toussaint B, Coste EU, Valette G, Van den Abbeele T, Varoquaux A, Veillon F, Vergez S, Wassef M. Mucoepidermoid carcinoma of salivary glands: A French Network of Rare Head and Neck Tumors (REFCOR) prospective study of 292 cases. Eur J Surg Oncol 2021; 47:1376-1383. [DOI: 10.1016/j.ejso.2020.11.123] [Citation(s) in RCA: 7] [Impact Index Per Article: 2.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/12/2020] [Revised: 10/31/2020] [Accepted: 11/13/2020] [Indexed: 12/18/2022] Open
|
5
|
Debbi K, Loganadane V G, Kinj R, Chapet S, Janoray G, Benezery K, Barillot I, Calais G. Stereotactic Ablative Radiation Therapy (CyberKnife) for Lung Oligometastases from Head and Neck Squamous Cell Carcinoma (HNSCC): Bi-Institutional Study. Int J Radiat Oncol Biol Phys 2020. [DOI: 10.1016/j.ijrobp.2020.07.1396] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/23/2022]
|
6
|
Debbi K, Chapet S, Kinj R, Janoray G, Rajasingham R, Bénézéry K, Barillot I, Calais G. Radiothérapie stéréotaxique par CyberKnife® des oligométastases pulmonaires des cancers de la tête et du cou : survie et facteurs pronostiques, une étude rétrospective multicentrique. Cancer Radiother 2019. [DOI: 10.1016/j.canrad.2019.07.007] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/26/2022]
|
7
|
Lizée T, Seegers V, Blanchecotte J, Rio E, Capitain O, Guérin-Meyer V, Legouté F, Gonzalez-Moya A, Calais G, Autret D, Mahé MA, Paumier A. Étude de phase 1 d’escalade de dose d’irradiation avec modulation d’intensité et boost intégré simultané dans la chimioradiothérapie pelvienne des cancers du bas et moyen rectum métastatiques synchrones. Cancer Radiother 2019. [DOI: 10.1016/j.canrad.2019.07.101] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/26/2022]
|
8
|
Scher N, Janoray G, Riet FG, Le Bayon AG, Debbi K, Lévy S, Louisot P, Garaud P, Chajon E, Barillot I, Salamé É, de Crevoisier R, Chapet S, Calais G. [Stereotactic body radiation therapy for hepatocellular carcinoma: Results from a retrospective multicentre study]. Cancer Radiother 2019; 23:104-115. [PMID: 30952560 DOI: 10.1016/j.canrad.2018.07.138] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/18/2018] [Revised: 07/24/2018] [Accepted: 07/29/2018] [Indexed: 01/27/2023]
Abstract
PURPOSE The purpose of this paper was to describe local control, overall survival, progression-free survival and toxicity of CyberKnife®-based stereotactic body radiation therapy of hepatocellular carcinoma. MATERIAL AND METHODS Records of all the patients treated for hepatocellular carcinoma at the Eugene-Marquis cancer centre, Rennes and the Bretonneau hospital, Tours (France), between November 2010 and December 2016, were reviewed. Radiation therapy was performed as a salvage treatment, while awaiting liver transplantation or if no other treatment was possible. RESULTS One hundred and thirty-six patients were consecutively included in the study. The median follow-up was 13months. Median total dose prescribed, fractionation and overall treatment time were respectively 45Gy, three fractions and 5 days. Overall survival, progression-free survival and local control rates at 1year and 2years were 79.8 % and 63.5 %, 61.3 % and 39.4 %; 94.5 % and 91 %. Two grade 3 acute toxicity events and two grade 4 late toxicity events corresponding to a duodenal ulcer have been reported. Seven patients underwent classic radiation-induced hepatitis and 13 patients showed non-classical radiation-induced hepatitis. Barcelona Clinic Liver Cancer stage, World Health Organisation grade and planning target volume were correlated with overall survival in univariate Cox analysis. CONCLUSION Stereotactic body radiation therapy is effective and well-tolerated for inoperable hepatocellular carcinoma or as a bridge to liver transplantation. Toxicity is mainly related to cirrhotic background and requires a selection of patients and strict dose constraints.
Collapse
Affiliation(s)
- N Scher
- Centre Henry-S.-Kaplan, clinique d'oncologie radiothérapie, CHRU de Tours, 2, boulevard Tonnellé, 37044 Tours, France.
| | - G Janoray
- Centre Henry-S.-Kaplan, clinique d'oncologie radiothérapie, CHRU de Tours, 2, boulevard Tonnellé, 37044 Tours, France
| | - F-G Riet
- Département de radiothérapie, centre de lutte contre le cancer Eugène-Marquis, avenue de la Bataille-Flandres-Dunkerque, 35000 Rennes, France
| | - A-G Le Bayon
- Centre Henry-S.-Kaplan, clinique d'oncologie radiothérapie, CHRU de Tours, 2, boulevard Tonnellé, 37044 Tours, France
| | - K Debbi
- Centre Henry-S.-Kaplan, clinique d'oncologie radiothérapie, CHRU de Tours, 2, boulevard Tonnellé, 37044 Tours, France
| | - S Lévy
- Centre Henry-S.-Kaplan, clinique d'oncologie radiothérapie, CHRU de Tours, 2, boulevard Tonnellé, 37044 Tours, France
| | - P Louisot
- Centre Henry-S.-Kaplan, clinique d'oncologie radiothérapie, CHRU de Tours, 2, boulevard Tonnellé, 37044 Tours, France
| | - P Garaud
- Centre Henry-S.-Kaplan, clinique d'oncologie radiothérapie, CHRU de Tours, 2, boulevard Tonnellé, 37044 Tours, France
| | - E Chajon
- Département de radiothérapie, centre de lutte contre le cancer Eugène-Marquis, avenue de la Bataille-Flandres-Dunkerque, 35000 Rennes, France
| | - I Barillot
- Centre Henry-S.-Kaplan, clinique d'oncologie radiothérapie, CHRU de Tours, 2, boulevard Tonnellé, 37044 Tours, France
| | - É Salamé
- Département de chirurgie digestive, oncologique et transplantation hépatique, CHRU de Tours, 37044 Chambray-lès-Tours, France
| | - R de Crevoisier
- Département de radiothérapie, centre de lutte contre le cancer Eugène-Marquis, avenue de la Bataille-Flandres-Dunkerque, 35000 Rennes, France
| | - S Chapet
- Centre Henry-S.-Kaplan, clinique d'oncologie radiothérapie, CHRU de Tours, 2, boulevard Tonnellé, 37044 Tours, France
| | - G Calais
- Centre Henry-S.-Kaplan, clinique d'oncologie radiothérapie, CHRU de Tours, 2, boulevard Tonnellé, 37044 Tours, France
| |
Collapse
|
9
|
Scher N, Riet F, Janoray G, Debbi K, Levy S, Louisot P, Chajon E, Salame E, Barillot I, De Crevoisier R, Calais G, Chapet S. EP-1414 SBRT for the treatment of hepatocellular carcinoma: a retrospective multicenter study. Radiother Oncol 2019. [DOI: 10.1016/s0167-8140(19)31834-1] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/27/2022]
|
10
|
Scher N, Chapet S, Riet FG, Janoray G, Debbi K, Lévy S, Chajon E, Barillot I, de Crevoisier R, Calais G. Radiothérapie en conditions stéréotaxiques du carcinome hépatocellulaire : étude rétrospective multicentrique. Cancer Radiother 2018. [DOI: 10.1016/j.canrad.2018.07.022] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/28/2022]
|
11
|
Lévy S, Chapet S, Scher N, Debbi K, Ruffier A, Bernadou G, Pointreau Y, Calais G. Reirradiation of gliomas under stereotactic conditions: Prognostic factors for survival without relapse or side effects, a retrospective study at Tours regional university hospital (France). Cancer Radiother 2017; 21:759-765. [PMID: 29128197 DOI: 10.1016/j.canrad.2017.05.006] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/19/2017] [Revised: 05/06/2017] [Accepted: 05/16/2017] [Indexed: 01/18/2023]
Abstract
PURPOSE To search for factors correlated with relapse-free survival following stereotactic reirradiation in patients with recurrent glioma following radiochemotherapy and evaluate tolerance to this treatment. PATIENTS AND METHODS Initial radiotherapy was given according to the protocol of Stupp and al. Reirradiation was performed using the CyberKnife® system. Patients could have had surgical resection initially and at the time of recurrence. We analysed 13 patients treated between July 2010 and September 2014. The median age was 55 years. The doses delivered ranged from 20 to 36Gy, in one to ten fractions. RESULTS Median survival after stereotactic radiotherapy was 14 months. Survival without relapse was 3.7 months. Factors significantly influencing duration of relapse-free survival were: age (P=0.04), total dose (P=0.02), dose per fraction (P=0.04) and number of fractions (P=0.01). We found no correlation between gross tumour volume, clinical target volume, grade of tumour or prescription isodose and relapse-free survival following radiochemotherapy. Three patients developed radionecrosis. CONCLUSION Reirradiation under stereotactic conditions is well tolerated. A dose of more than 30Gy delivered in 5 or more fractions seems to prolong relapse-free survival.
Collapse
Affiliation(s)
- S Lévy
- Radiotherapy Department, CHRU de Tours, Corad, 2, boulevard Tonnelé, 37000 Tours, France.
| | - S Chapet
- Radiotherapy Department, CHRU de Tours, Corad, 2, boulevard Tonnelé, 37000 Tours, France
| | - N Scher
- Radiotherapy Department, CHRU de Tours, Corad, 2, boulevard Tonnelé, 37000 Tours, France
| | - K Debbi
- Radiotherapy Department, CHRU de Tours, Corad, 2, boulevard Tonnelé, 37000 Tours, France
| | - A Ruffier
- Radiotherapy Department, CHRU de Tours, Corad, 2, boulevard Tonnelé, 37000 Tours, France
| | - G Bernadou
- Radiotherapy Department, CHRU de Tours, Corad, 2, boulevard Tonnelé, 37000 Tours, France
| | - Y Pointreau
- Radiotherapy Department, CHRU de Tours, Corad, 2, boulevard Tonnelé, 37000 Tours, France; Institut interrégional de cancérologie centre Jean-Bernard, clinique Victor-Hugo, 9, rue Beauverger, 72000 Le Mans, France
| | - G Calais
- Radiotherapy Department, CHRU de Tours, Corad, 2, boulevard Tonnelé, 37000 Tours, France
| |
Collapse
|
12
|
Pointreau Y, Caron D, Septans AL, Denis F, Ganem G, Voog E, Lafond C, Dupuis O, Domont J, Roche S, Bourgeois H, Calais G. Série de radiothérapie en conditions stéréotaxiques de métastases cérébrales précédée ou non d’une irradiation panencéphalique dite prophylactique. Cancer Radiother 2017. [DOI: 10.1016/j.canrad.2017.08.014] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/18/2022]
|
13
|
Robert A, Pointreau Y, Janoray G, Bardet É, Fesneau M, Garaud P, Chapet S, Lafond C, Dupuis O, Calais G. A large French multicenter retrospective series of T1-T2N0 vocal cords carcinomas treated with exclusive irradiation. Cancer Radiother 2017; 21:286-290. [DOI: 10.1016/j.canrad.2017.01.015] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/11/2016] [Revised: 01/25/2017] [Accepted: 01/27/2017] [Indexed: 10/19/2022]
|
14
|
Camus F, Munier O, Calais G, Barillot I. Évaluation de la réponse tumorale après irradiation stéréotaxique de cancers bronchiques non à petites cellules classés T1T2N0M0 selon l’algorithme de Huang : étude rétrospective de 94 cas. Rev Mal Respir 2017. [DOI: 10.1016/j.rmr.2016.10.023] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/20/2022]
|
15
|
Lizée T, Métayer Y, Benoît D, Denis F, Peyraga G, Calais G, Pointreau Y. Radiothérapie stéréotaxique intracrânienne de métastase cérébrale unique : comparaison dosimétrique entre CyberKnife® et TrueBeam® avec des arcs dynamiques conformés. Cancer Radiother 2016. [DOI: 10.1016/j.canrad.2016.08.090] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/25/2022]
|
16
|
Janoray G, Pointreau Y, Garaud P, Chapet S, Alfonsi M, Sire C, Jadaud E, Calais G. Résultats à long terme de l’essai de phase III Gortec 2000-01 sur la chimiothérapie d’induction par cisplatine, 5-fluorouracile avec ou sans docétaxel pour la préservation laryngée. Cancer Radiother 2016. [DOI: 10.1016/j.canrad.2016.08.114] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/24/2022]
|
17
|
Théron A, Chapet S, Bernadou G, Calais G, Morinière S, Pointreau Y. Réirradiation en condition stéréotaxiques par CyberKnife® des cancers des sinus de la face récidivants. Cancer Radiother 2016. [DOI: 10.1016/j.canrad.2016.08.017] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/26/2022]
|
18
|
Meyer E, Pasquier D, Stefan D, Bernadou G, Carrie C, Calais G, Théodore C, Bossi A, Hennequin C, Lagrange J, Dugue A, Clarisse B, Habrand J, Joly F. Radiothérapie stéréotaxique pour la prise en charge des métastases osseuses du cancer du rein : étude rétrospective du Groupe d’études des tumeurs urogénitales (Gétug). Cancer Radiother 2016. [DOI: 10.1016/j.canrad.2016.07.048] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/25/2022]
|
19
|
Pointreau Y, Azzopardi N, Ternant D, Calais G, Paintaud G. Association radiothérapie cétuximab dans les cancers ORL : impact sur la survie globale du grade de radiodermite et de la clairance globale. Cancer Radiother 2016. [DOI: 10.1016/j.canrad.2016.08.016] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/27/2022]
|
20
|
TAO Y, Aupérin A, Graff P, Gregoire V, Maingon P, Calais G, Gery B, Martin L, Alfonsi M, Desprez P, Bardet E, Rives M, Geoffrois L, Tuchais C, Dupuis O, Guerif S, Lapeyre M, Sire C, Bourhis J. Concurrent Chemoradiation Therapy Versus Acceleration of Radiation Therapy With or Without Concurrent Chemotherapy in Locally Advanced Head and Neck Carcinoma (GORTEC 99-02): 7-Year Survival Data From a Phase 3 Randomized Trial and Prognostic Factors. Int J Radiat Oncol Biol Phys 2016. [DOI: 10.1016/j.ijrobp.2016.06.1443] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/20/2022]
|
21
|
Pointreau Y, Lafond C, Legouté F, Trémolières P, Servagi-Vernat S, Giraud P, Maingon P, Calais G, Lapeyre M. Radiothérapie des cancers du larynx. Cancer Radiother 2016; 20 Suppl:S131-5. [DOI: 10.1016/j.canrad.2016.07.018] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/21/2022]
|
22
|
Bernadou G, Barillot I, Régnault-Bougnoux A, Calais G, Chapet S, Ruffier-Loubière A. Analyse comparative de la toxicité tardive de la curiethérapie de haut débit de dose et de celle de bas débit de dose du cancer de l’endomètre. Cancer Radiother 2015. [DOI: 10.1016/j.canrad.2015.07.121] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/25/2022]
|
23
|
Ruffier-Loubière A, Janoray G, Chapet S, de Calan L, Dumont P, Dorval É, Orain I, Calais G. [Long-term outcome of neoadjuvant radiochemotherapy followed by surgery for esophageal cancer: a single institution retrospective study of 102 patients]. Cancer Radiother 2015. [PMID: 26215366 DOI: 10.1016/j.canrad.2015.04.004] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/23/2022]
Abstract
PURPOSE AND OBJECTIVES To report survival and morbidity of a large homogeneous cohort of patients with a locally advanced esophageal or cardia carcinoma and put in evidence predictive factors of locoregional control and survival. PATIENTS AND METHODS Hundred and two patients were treated at the university hospital of Tours between 1990 and 2010 and received neo-adjuvant chemoradiation therapy with external irradiation (40Gy-44Gy) and two courses of chemotherapy (5-fluoro-uracile and cisplatine). Esophagectomy associated with lymph node dissection was performed about ten weeks after the end of chemoradiation therapy. RESULTS The median follow-up was 22.4 months [6-185 months]. The overall survival rates at 2 and 5years were 53% and 27%, respectively. The median overall survival was estimated at 27months. The overall 2-year survival between patients "responders" and patients "non-responders" was 67% vs 26%, respectively (P<0.0001). In case of histological response, there was a benefit in terms of overall survival (P<0.0001), locoregional control (P<0.0036) and disease-free survival (P<0.001). Overall survival at 2years was 64% for ypN0 group vs 32% for ypN1 group (P<0.0001). The median survival was estimated at 37months against 15months in the absence of lymph node involvement (P<0.0001). CONCLUSION Our results in terms of survival, tolerance and morbidity and mortality were comparable to those in the literature. Complete histological response of lymph node was associated with an improvement of local control, disease-free survival and overall survival.
Collapse
Affiliation(s)
- A Ruffier-Loubière
- Clinique d'oncologie-radiothérapie, hôpital Bretonneau, CHRU de Tours, 2, boulevard Tonnellé, 37044 Tours cedex 9, France
| | - G Janoray
- Clinique d'oncologie-radiothérapie, hôpital Bretonneau, CHRU de Tours, 2, boulevard Tonnellé, 37044 Tours cedex 9, France.
| | - S Chapet
- Clinique d'oncologie-radiothérapie, hôpital Bretonneau, CHRU de Tours, 2, boulevard Tonnellé, 37044 Tours cedex 9, France
| | - L de Calan
- Service de chirurgie digestive, hôpital Trousseau, CHRU de Tours, avenue de la République, 37170 Chambray-les-Tours, France
| | - P Dumont
- Service de chirurgie thoracique, hôpital Trousseau, CHRU de Tours, avenue de la République, 37170 Chambray-les-Tours, France
| | - É Dorval
- Service de gastroentérologie, hôpital Trousseau, CHRU de Tours, avenue de la République, 37170 Chambray-les-Tours, France
| | - I Orain
- Service d'anatomopathologie, hôpital Trousseau, CHRU de Tours, avenue de la République, 37170 Chambray-les-Tours, France
| | - G Calais
- Clinique d'oncologie-radiothérapie, hôpital Bretonneau, CHRU de Tours, 2, boulevard Tonnellé, 37044 Tours cedex 9, France
| |
Collapse
|
24
|
Janoray G, Reynaud-Bougnoux A, Ruffier-loubiere A, Bernadou G, Pointreau Y, Calais G. EP-1224 Stereotactic Body Re-irradiation Therapy for locally recurrent prostate cancer after EBRT. Radiother Oncol 2015. [DOI: 10.1016/s0167-8140(15)41216-2] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022]
|
25
|
Janoray G, Bougnoux-Reynaud A, Bernadou G, Ruffier-Loubière A, Calais G. Radiothérapie stéréotaxique robotisée dans la prise en charge des rechutes en territoire irradié des cancers de la prostate : faisabilité et tolérance. Cancer Radiother 2014. [DOI: 10.1016/j.canrad.2014.07.008] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/25/2022]
|
26
|
Janoray G, Chapet S, Ruffier-Loubière A, Bernadou G, Pointreau Y, Calais G. Robotic stereotactic body radiation therapy for tumors of the liver: radiation-induced liver disease, incidence and predictive factors. Cancer Radiother 2014; 18:191-7. [PMID: 24837351 DOI: 10.1016/j.canrad.2014.03.009] [Citation(s) in RCA: 17] [Impact Index Per Article: 1.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/20/2014] [Revised: 03/13/2014] [Accepted: 03/26/2014] [Indexed: 12/14/2022]
Abstract
PURPOSE Robotic stereotactic body radiation therapy is a new option to treated unresecable liver tumours. The objectives were to assess the tolerance of this technique, to identify predictive factors for toxicity and evaluate the efficiency of this treatment. PATIENTS AND METHODS From June 2010 to November 2012, robotic stereotactic body radiation therapy was proposed for 56 patients with unresecable hepatocellular carcinomas (23 patients) or hepatic metastases (41 patients). Two or less hepatic lesions, lesion size under 75 mm and WHO score under 3 were selection criteria. The prescribed dose was 45 Gy/3 fractions or 60 Gy/3 fractions. The primary end-point was toxicity, using the radiation-induced liver disease definition and to identify predictive factors. Secondary end-points were in-field local control and overall survival. RESULTS The median follow-up was 12.5 months. The one-year local control rate and the one-year overall survival rate were 64% [CI95%: 48.2 to 76.5%] and 89% [CI95%: 76 to 95%], respectively. For patient treated with a total dose of 60 Gy, no one experienced recurrence. According to the definition we took, radiation-induced liver disease rate was 0 or 9%. A lesion size at least 35 mm was a predictive factor to liver toxicity (P=0.01). CONCLUSION Using robotic stereotactic body radiation therapy, the incidence of radiation-induced liver disease is weak and spontaneously reversible. Prospective studies are required to put in evidence other predictive factors of radiation-induced liver disease and confirm the optimal dose treatment.
Collapse
Affiliation(s)
- G Janoray
- Oncology-Radiotherapy Department, Henry S. Kaplan Cancer Center, CHRU de Tours, 2 boulevard Tonnellé, 37000 Tours, France.
| | - S Chapet
- Oncology-Radiotherapy Department, Henry S. Kaplan Cancer Center, CHRU de Tours, 2 boulevard Tonnellé, 37000 Tours, France
| | - A Ruffier-Loubière
- Oncology-Radiotherapy Department, Henry S. Kaplan Cancer Center, CHRU de Tours, 2 boulevard Tonnellé, 37000 Tours, France
| | - G Bernadou
- Oncology-Radiotherapy Department, Henry S. Kaplan Cancer Center, CHRU de Tours, 2 boulevard Tonnellé, 37000 Tours, France
| | - Y Pointreau
- Oncology-Radiotherapy Department, Henry S. Kaplan Cancer Center, CHRU de Tours, 2 boulevard Tonnellé, 37000 Tours, France
| | - G Calais
- Oncology-Radiotherapy Department, Henry S. Kaplan Cancer Center, CHRU de Tours, 2 boulevard Tonnellé, 37000 Tours, France
| |
Collapse
|
27
|
Calais G, Janoray G, Chapet S, Ruffier-Loubiere A, Pichon E, Diot P, Bernadou G, Barillot I. EP-1387: Pulmonary oligometastases: Stereotactic Body Radiation Therapy as a new option? Radiother Oncol 2014. [DOI: 10.1016/s0167-8140(15)31505-x] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/27/2022]
|
28
|
Janoray G, Chapet S, Ruffier-Loubière A, Bernadou G, Barillot I, Calais G. Oligométastases pulmonaires : la radiothérapie stéréotaxique robotisée comme une nouvelle option ? Rev Mal Respir 2014. [DOI: 10.1016/j.rmr.2013.10.439] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/25/2022]
|
29
|
Calais G, Chapet S, Ruffier-Loubière A, Bernadou G. Cancers des voies aérodigestives supérieures : le retour de la chimiothérapie néoadjuvante ? Cancer Radiother 2013; 17:498-501. [DOI: 10.1016/j.canrad.2013.06.038] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/11/2013] [Accepted: 06/19/2013] [Indexed: 11/28/2022]
|
30
|
Janoray G, Chapet S, Ruffier-Loubière A, Bernadou G, Pointreau Y, Calais G. Radiothérapie stéréotaxique des métastases hépatiques et des hépatocarcinomes. Hépatopathie radio-induite, incidence, facteurs prédictifs et résultats carcinologiques. Cancer Radiother 2013. [DOI: 10.1016/j.canrad.2013.07.013] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/26/2022]
|
31
|
Munier O, Barillot I, Calais G, Bera G, Pointreau Y, Ruffier-Loubière A, Chapet S. Irradiation stéréotaxique robotisée des tumeurs primitives pulmonaires de stade T1 T2 N0 inopérables. Expérience préliminaire du centre hospitalier universitaire de Tours. Cancer Radiother 2013. [DOI: 10.1016/j.canrad.2013.07.057] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/26/2022]
|
32
|
Moulin S, Salleron J, Calais G, Maurage CA, Kalaria R, Pasquier F, Deramecourt V. Apport du score cérébrovasculaire neuropathologique à l’étude de l’impact de la charge vasculaire sur les démences. Rev Neurol (Paris) 2013. [DOI: 10.1016/j.neurol.2013.01.022] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/15/2022]
|
33
|
Atean I, Pointreau Y, Rosset P, Garaud P, De-Pinieux G, Calais G. Prognostic factors of extremity soft tissue sarcoma in adults. A single institutional analysis. Cancer Radiother 2012; 16:661-6. [PMID: 23142179 DOI: 10.1016/j.canrad.2012.05.021] [Citation(s) in RCA: 13] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/18/2012] [Revised: 03/13/2012] [Accepted: 05/25/2012] [Indexed: 10/27/2022]
Abstract
PURPOSE To analyse the prognostic factors for patients treated with limb sparing surgery and radiation for extremity soft tissue sarcoma (E-STS). PATIENTS AND METHODS Medical records of 87 patients with limb sparing surgery and radiation for E-STS were reviewed retrospectively. Disease-free survival (DFS) and disease-specific survival (DSS) were estimated and factors potentially influencing these outcomes were analysed. RESULTS With a mean follow-up of 69months, most recurrences occurred within the first 2years. Extent of resection margin was found to improve DFS (P=0.002) and DSS (P=0.002). Brachytherapy combined with external beam radiotherapy (EBRT) improved DFS (P=0.034) and DSS (P=0.019). Tumor size (<10cm) was related to DSS (P=0.043) and its relation to DFS was almost significant (P=0.057). Short time interval between surgery and radiotherapy (≤50days) had an impact only on DSS (P=0.030). CONCLUSION Extent of resection margin and use of brachytherapy combined with EBRT seem to improve the prognosis of E-STS. Small tumor size and short time interval between radiotherapy and surgery seem also to improve the outcome of E-STS. This study was limited by inadequate power and low number of recurrences. Larger randomised studies are needed to confirm these results.
Collapse
Affiliation(s)
- I Atean
- Department of Radiation Oncology, Henry-Kaplan Oncology Center, CHRU de Tours, 2, boulevard Tonnellé, 37044 Tours, France.
| | | | | | | | | | | |
Collapse
|
34
|
Lenne B, Nandrino JL, Sequeira H, Leuse D, Calais G, Hautecoeur P. Deficit in Facial Emotion Recognition and Interhemispheric Transfer in Relapsing-Remitting Multiple Sclerosis (RRMS) (P04.117). Neurology 2012. [DOI: 10.1212/wnl.78.1_meetingabstracts.p04.117] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/15/2022] Open
|
35
|
Bonnetain F, Bosset JF, Gerard JP, Calais G, Conroy T, Mineur L, Bouché O, Maingon P, Chapet O, Radosevic-Jelic L, Methy N, Collette L. What is the clinical benefit of preoperative chemoradiotherapy with 5FU/leucovorin for T3-4 rectal cancer in a pooled analysis of EORTC 22921 and FFCD 9203 trials: surrogacy in question? Eur J Cancer 2012; 48:1781-90. [PMID: 22507892 DOI: 10.1016/j.ejca.2012.03.016] [Citation(s) in RCA: 84] [Impact Index Per Article: 7.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/22/2011] [Revised: 02/22/2012] [Accepted: 03/19/2012] [Indexed: 01/08/2023]
Abstract
BACKGROUND Two phase III trials of neoadjuvant treatment in T3-4 rectal cancer established that adding chemotherapy (CRT) to radiotherapy (RT) improves pathological complete response (pCR) and local control (LC). We combined trials to assess the clinical benefit of CRT on overall (OS) and progression free survival (PFS) and to explore the surrogacy of pCR and LC. PATIENTS AND METHODS Individual patient data from European Organisation for Research and Treatment of Cancer (EORTC) 22921 (1011 patients) and FFCD 9203 (756 patients) were pooled. Meta-analysis methodology was used to compare neoadjuvant CRT to RT for OS, PFS LC and distant progression (DP). Weighted linear regression was used to estimate trial-level association (surrogacy R(2)) between treatment effects on candidate surrogate (pCR, LC, DP) and OS. RESULTS The median follow-up was 5.6 years. Compared to RT (881 pts), CRT (886 pts) did not prolong OS, DP or PFS. The 5-y OS-rate was 66.3% with CRT versus 65.9% in RT (hazard ratios (HR) = 1.04 {0.88-1.21}). CRT significantly improved LC (HR = 0.54, 95%confidence interval (CI): 0.41-0.72). PFS was validated as surrogate for OS with R(2) = 0.88. Neoadjuvant treatment effects on LC (R(2) = 0.17) or DP (R(2) = 0.31) did not predict effects on OS. CONCLUSION Preoperative CRT does not prolong OS or PFS. pCR or LC do not qualify as surrogate for PFS or OS while PFS is surrogate. Phase III trials should use OS or PFS as primary endpoint.
Collapse
Affiliation(s)
- F Bonnetain
- Biostatistics and Epidemiology Department, EA 4184 Centre Georges François Leclerc & FFCD, Dijon, France.
| | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
36
|
Kwiatkowski A, Gallois J, Bilbault N, Calais G, Mackowiak A, Hautecoeur P. Herpes encephalitis during natalizumab treatment in multiple sclerosis. Mult Scler 2011; 18:909-11. [DOI: 10.1177/1352458511428082] [Citation(s) in RCA: 25] [Impact Index Per Article: 1.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
In this case report we describe the first non-fatal herpes simplex virus encephalitis (HSE) case with natalizumab for multiple sclerosis (MS). A 36-year-old woman, previously treated with immunomodulatory and immunosuppressive drugs for MS, developed acute encephalitis after 6 monthly natalizumab perfusions. Brain imaging demonstrated suggestive bi-temporal lesions. Herpes simplex virus type-1 DNA was detected in cerebrospinal fluid. The patient improved gradually after a 21-day course of intravenous acyclovir, but neuropsychiatric changes remained 5 months later. Our non-fatal case of HSE and other reported cases of herpes infections provide evidence of an increased risk with natalizumab and point to the need for clinicians to maintain awareness.
Collapse
Affiliation(s)
- A Kwiatkowski
- PRES Lille Nord de France, Université Catholique de Lille, Groupe Hospitalier de l’Institut Catholique de Lille / Faculté Libre de Médecine, Clinique de Neurologie, Lille, France
| | - J Gallois
- PRES Lille Nord de France, Université Catholique de Lille, Groupe Hospitalier de l’Institut Catholique de Lille / Faculté Libre de Médecine, Clinique de Neurologie, Lille, France
| | - N Bilbault
- PRES Lille Nord de France, Université Catholique de Lille, Groupe Hospitalier de l’Institut Catholique de Lille / Faculté Libre de Médecine, Clinique de Neurologie, Lille, France
| | - G Calais
- PRES Lille Nord de France, Université Catholique de Lille, Groupe Hospitalier de l’Institut Catholique de Lille / Faculté Libre de Médecine, Clinique de Neurologie, Lille, France
| | - A Mackowiak
- PRES Lille Nord de France, Université Catholique de Lille, Groupe Hospitalier de l’Institut Catholique de Lille / Faculté Libre de Médecine, Clinique de Neurologie, Lille, France
| | - P Hautecoeur
- PRES Lille Nord de France, Université Catholique de Lille, Groupe Hospitalier de l’Institut Catholique de Lille / Faculté Libre de Médecine, Clinique de Neurologie, Lille, France
| |
Collapse
|
37
|
Hennequin C, Calais G, Antoun S, Durand JP, Krakowski I, Senesse P, Hébuterne X. Calories : une étude nationale observationnelle sur les pratiques nutritionnelles en oncologie en France. Cancer Radiother 2011. [DOI: 10.1016/j.canrad.2011.07.024] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/17/2022]
|
38
|
Bosset J, Puyraveau M, Mineur L, Calais G, Bardet E, Maingon P, Bolla M, Collette L, Mercier M. 6018 POSTER DISCUSSION EORTC 22921 Rectal Cancer Trial: Quality of Life (QoL) and Functional Outcome 5 Years After Treatment. Eur J Cancer 2011. [DOI: 10.1016/s0959-8049(11)71663-x] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/17/2022]
|
39
|
Durand J, Antoun S, Calais G, Hennequin C, Krakowski I, Senesse P, Hébuterne X. 3046 POSTER Results of a Nationwide Observational Study on Nutritional Practices Amongst French Cancer Physicians. Eur J Cancer 2011. [DOI: 10.1016/s0959-8049(11)71119-4] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/17/2022]
|
40
|
Leclerc M, Maingon P, Hamoir M, Bonnetain F, Calais G, Nuyts S, Serre A, Gregoire V. 8515 POSTER DISCUSSION A Dose Escalation Study With Intensity Modulated Radiation Therapy (IMRT) in Moderately Advanced (T2N0, T2N1, T3N0) Squamous Cell Carcinomas (SCC) of the Oropharynx, Larynx and Hypopharynx Using a Simultaneous Integrated Boost (SIB) Approach. Eur J Cancer 2011. [DOI: 10.1016/s0959-8049(11)72157-8] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022]
|
41
|
Lefebvre J, Pointreau Y, Rolland F, Alfonsi M, Baudoux A, Sire C, De Raucourt D, Bardet E, Tuchais C, Garaud P, Calais G. Sequential chemoradiotherapy (SCRT) for larynx preservation (LP): Results of the randomized phase II TREMPLIN study. J Clin Oncol 2011. [DOI: 10.1200/jco.2011.29.15_suppl.5501] [Citation(s) in RCA: 14] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
|
42
|
Bonnetain F, Bosset J, Gerard J, Calais G, Conroy T, Mineur L, Bouche O, Maingon P, Chapet O, Radosevic-Jelic L, Methy N, Collette L. An analysis of preoperative chemoradiotherapy with 5FU/leucovorin for T3-4 rectal cancer on survival in a pooled analysis of EORTC 22921 and FFCD 9203 trials: Surrogacy in question? J Clin Oncol 2011. [DOI: 10.1200/jco.2011.29.15_suppl.3506] [Citation(s) in RCA: 7] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
|
43
|
Pointreau Y, Debelleix C, Garaud P, Chapet S, Sire C, Tuchais C, Tortochaux J, Faivre S, Guérif S, Alfonsi M, Calais G. 135 oral LONG TERM RESULTS OF THE GORTEC 2000-01 LARYNX PRESERVATION RANDOMIZED TRIAL USING A COMPOSITE FUNCTIONAL ENDPOINT. Radiother Oncol 2011. [DOI: 10.1016/s0167-8140(11)70257-2] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/26/2022]
|
44
|
Blanchard P, Bourredjem A, Bourhis J, Hitt R, Posner M, Vermorken J, Calais G, Paccagnella A, Pignong J. TAXANE-CISPLATIN-5FU AS INDUCTION CHEMOTHERAPY IN LOCALLY ADVANCED HEAD AND NECK SQUAMOUS CELL CARCINOMA: AN INDIVIDUAL PATIENT DATA META-ANALYSIS OF THE MACH-NC GROUP. Radiother Oncol 2011. [DOI: 10.1016/s0167-8140(11)70005-6] [Citation(s) in RCA: 8] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/26/2022]
|
45
|
|
46
|
Tiv M, Puyraveau M, Mineur L, Calais G, Maingon P, Bardet É, Mercier M, Bosset JF. Long-term quality of life in patients with rectal cancer treated with preoperative (chemo)-radiotherapy within a randomized trial. Cancer Radiother 2010; 14:530-4. [DOI: 10.1016/j.canrad.2010.06.017] [Citation(s) in RCA: 45] [Impact Index Per Article: 3.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/26/2010] [Accepted: 06/08/2010] [Indexed: 11/27/2022]
|
47
|
Bera G, Pointreau Y, Bramoullé C, Calais G, Barillot I. Evaluation d’un atlas de segmentation automatique de la sphère ORL. Cancer Radiother 2010. [DOI: 10.1016/j.canrad.2010.07.615] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/25/2022]
|
48
|
Debelleix C, Pointreau Y, Lafond C, Denis F, Calais G, Bourhis JH. [Normal tissue tolerance to external beam radiation therapy: larynx and pharynx]. Cancer Radiother 2010; 14:301-6. [PMID: 20598610 DOI: 10.1016/j.canrad.2010.05.002] [Citation(s) in RCA: 13] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/03/2010] [Revised: 05/05/2010] [Accepted: 05/07/2010] [Indexed: 11/15/2022]
Abstract
For head and neck cancers, the radiation dose usually needed to sterilize a macroscopic tumour is at least 70 Gy in conventional fractionation. In the larynx, this dose level enables optimal tumour control while exposing the patient to a limited risk of severe complications. For oropharynx and nasopharynx tumors, it is sometimes possible to limit the dose received by the larynx according to the extent of the primary lesion. Thus, if the tumour constraints permit, the maximum dose to the larynx must be less than 63 to 66 Gy. To reduce the risk of laryngeal edema, it is recommended if possible to limit the mean non-involved larynx dose to 40 to 45 Gy. In the pharynx, literature's data suggested to minimize the volume of the pharyngeal constrictor muscles receiving a dose greater than or equal to 60 Gy. Limiting the volume receiving a dose greater than or equal to 50 Gy reduces the risk of dysphagia. These dose constraints should be tailored to each patient taking into account the extent of the initial primary lesion, the possible addition of chemotherapy or a modified fractionation radiotherapy.
Collapse
Affiliation(s)
- C Debelleix
- Service de Radiothérapie, Centre Hospitalier Dax-Côte d'Argent, Boulevard Yves-du-Manoir, 40100 Dax, France
| | | | | | | | | | | |
Collapse
|
49
|
Calais G, Chapet S, Pointreau Y, Bardet E, Sire C, Germain T. Radiation alone (RT) versus RT with concomitant chemotherapy (CT) in stages III and IV oropharynx carcinoma: Ten-year results of the 94-01 GORTEC randomized study. J Clin Oncol 2010. [DOI: 10.1200/jco.2010.28.15_suppl.5516] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
|
50
|
Calais G, Pochat-Jimenez G, Chapet S, Morinière S, Beutter P. Cervical Lymph Node Metastasis from Squamous Cell Carcinoma with Unknown Primary Site: Bilateral versus Ipsilateral Irradiation. Int J Radiat Oncol Biol Phys 2009. [DOI: 10.1016/j.ijrobp.2009.07.916] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/20/2022]
|